TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31116190

Group type: EXPERIMENTAL
Intervention: Fixed-on-1 (Fo1) group with 8 to 10 teeth prostheses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fixed-on-2 (Fo2) group with 12 teeth prostheses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fixed-on-1 (Fo1) group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fixed-on-2 (Fo2) group
Number of subjects: 20
Study: 28583143

Group type: EXPERIMENTAL
Intervention: Enhanced SleepTrackTXT2 intervention involving text-message assessments and behavior change messages.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving text messages that only include assessments.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced SleepTrackTXT2 intervention.
Number of subjects: 0
Study: 25879224

Group type: EXPERIMENTAL
Intervention: Exposure to RTI symptoms
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Exposure to GTI symptoms
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Reported exposure outside the workplace for RTI
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Reported exposure outside the workplace for GTI
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Designated RTI episodes without reported exposure
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Designated GTI episodes without reported exposure
Number of subjects: 230
Study: 23831866

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 10
Study: 21402624

Group type: EXPERIMENTAL
Intervention: Chronic IDA (n = 27)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Corrected IDA (n = 70)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Nonanemic (n = 64)
Number of subjects: 161
Study: 19490617

Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy after concurrent chemoradiotherapy
Number of subjects: 283
Study: 17461372

Group type: EXPERIMENTAL
Intervention: High social support
Number of subjects: 434

Group type: COMPARATOR
Intervention: Low social support
Number of subjects: 434
Study: 15514412

Group type: EXPERIMENTAL
Intervention: Active extended treatment
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Active brief treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo extended treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo brief treatment
Number of subjects: 160
Study: 11180305

Group type: EXPERIMENTAL
Intervention: Three methods of promoting secondary prevention of coronary heart disease
Number of subjects: 2142

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2142
Study: 9475021

Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.5% solution
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 7897085

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 64
Study: 2955980

Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol (200 micrograms)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol (200 micrograms) and inhaled ipratropium bromide (60 micrograms)
Number of subjects: 16
Study: 31009400

Group type: EXPERIMENTAL
Intervention: Enhanced peripheral nerve evaluation (ePNE) using tined quadripolar electrode leads over 6 weeks
Number of subjects: 45
Study: 28775677

Group type: EXPERIMENTAL
Intervention: BCI training sessions (n = 55), 10 sessions lasting up to 40 min each, involving motor imagery of opening the affected hand.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (n = 19), hand exoskeleton-driven movements independent of brain activity.
Number of subjects: 74
Study: 25788668

Group type: EXPERIMENTAL
Intervention: Driving simulation (DS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Executive functions (EFs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG theta waves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: fMRI connectivity analysis
Number of subjects: 0
Study: 23846568

Group type: COMPARATOR
Intervention: Not applicable (control group of women not on ART)
Number of subjects: 1285
Study: 21414053

Group type: EXPERIMENTAL
Intervention: Polyethylene covers
Number of subjects: 18

Group type: COMPARATOR
Intervention: Carbomer drops
Number of subjects: 18
Study: 19345771

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Therapy (CIT) for 10 consecutive weekdays, 6 hours a day, with trainer-supervised, functionally based activities using massed practice.
Number of subjects: 10
Study: 16989011

Group type: EXPERIMENTAL
Intervention: Flucloxacillin (2 g intravenous dose)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 618
Study: 15320655

Group type: EXPERIMENTAL
Intervention: Intense basketball-simulated exercise
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (asymptomatic men)
Number of subjects: 48
Study: 14599634

Group type: EXPERIMENTAL
Intervention: Intracoronary radiation (brachytherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0
Study: 10768434

Group type: EXPERIMENTAL
Intervention: ALA-PDT
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo-PDT
Number of subjects: 45
Study: 8617187

Group type: EXPERIMENTAL
Intervention: Parboiled rice with high amylose content
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Parboiled rice with low amylose content
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-parboiled rice
Number of subjects: 12

Group type: COMPARATOR
Intervention: White bread
Number of subjects: 12
Study: 1618212

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (50 mg patch, 10 mg.24 h-1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 h nitrate-free period
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 h nitrate-free period
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2931973

Group type: EXPERIMENTAL
Intervention: Copper gluconate (10 mg/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30380991

Group type: EXPERIMENTAL
Intervention: Ulnar shortening osteotomy with arthroscopic debridement
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ulnar shortening osteotomy alone
Number of subjects: 44
Study: 30672180

Group type: EXPERIMENTAL
Intervention: Acupoint group (acupuncture at Zhaohai (KI 6), Taichong (LR 3), Lingdao (HT 4), Neiguan (PC 6), Shenmen (HT 7), Danzhong (CV 17), Baihui (GV 20), Fengchi (GB 20))
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Non-acupoint group (acupuncture at points 0.5 cun next to the acupoints)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sham-acupoint group (acupuncture at unrelated acupoints)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Blank group (no treatment)
Number of subjects: 160
Study: 26725013

Group type: EXPERIMENTAL
Intervention: Outcome-based course design using concept mapping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Objective-based lectures
Number of subjects: 0
Study: 25377444

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg orally every 12 hours for 24 weeks
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 23148287

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Atazanavir plus ritonavir (ATV/r)
Number of subjects: 265
Study: 20393393

Group type: EXPERIMENTAL
Intervention: Behavioral Graded Activity (BGA) program
Number of subjects: 146

Group type: COMPARATOR
Intervention: Manual Therapy (MT)
Number of subjects: 146
Study: 18615666

Group type: EXPERIMENTAL
Intervention: 1 g calcium
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2,000 IU vitamin D(3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of 1 g calcium and 2,000 IU vitamin D(3)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16102292

Group type: EXPERIMENTAL
Intervention: Intravaginal probiotics (n = 50)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (n = 67)
Number of subjects: 117
Study: 12439553

Group type: EXPERIMENTAL
Intervention: 2.0 ml of hyperbaric 0.3% dibucaine
Number of subjects: 98

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 98
Study: 9934737

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg b.i.d.
Number of subjects: 271
Study: 8520158

Group type: EXPERIMENTAL
Intervention: 10% lipid emulsion (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 5% glucose solution (group B)
Number of subjects: 30
Study: 1967562

Group type: EXPERIMENTAL
Intervention: Xamoterol (0.2 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7002074

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) - total dose of 6.6 g over two weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metrifonate - one dose of 10 mg/kg body weight at ten-day intervals, three times
Number of subjects: 40
Study: 31234717

Group type: EXPERIMENTAL
Intervention: Depo-Provera®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31314918

Group type: EXPERIMENTAL
Intervention: R-CHOP-14
Number of subjects: 582

Group type: COMPARATOR
Intervention: R-CHOP-21
Number of subjects: 582
Study: 27709406

Group type: EXPERIMENTAL
Intervention: Coping Power Program
Number of subjects: 112

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 112
Study: 26488913

Group type: EXPERIMENTAL
Intervention: Recovery-oriented PSA video
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatable disease-oriented video (beyondblue)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 23437972

Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 μg/g plus betamethasone 0.5 mg/g (Daivobet® Gel)
Number of subjects: 579
Study: 21781152

Group type: EXPERIMENTAL
Intervention: linagliptin (5 mg once daily)
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 1058
Study: 19360866

Group type: EXPERIMENTAL
Intervention: Stent supported percutaneous coronary intervention (PCI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgical revascularization (CABG)
Number of subjects: 100
Study: 17081285

Group type: EXPERIMENTAL
Intervention: Dissemination of multidisciplinary guidelines on prescribing behaviour
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group of GPs not involved in guideline development
Number of subjects: 107
Study: 15318467

Group type: EXPERIMENTAL
Intervention: LMA-Classic
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Soft Seal laryngeal mask
Number of subjects: 200
Study: 11402631

Group type: EXPERIMENTAL
Intervention: Intravenous tacrolimus 0.020 mg/kg IBW over 4 hours
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral tacrolimus approximately 0.12 mg/kg IBW
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous tacrolimus 0.020 mg/kg over 4 hours (normal subjects)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral tacrolimus 5 mg (0.065 mg/kg) (normal subjects)
Number of subjects: 6
Study: 9768401

Group type: EXPERIMENTAL
Intervention: Continuation of aspirin intake (Group A)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cessation of aspirin intake for 2 to 5 days before surgery (Group B)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cessation of aspirin intake for 7 to 10 days before surgery (Group C)
Number of subjects: 61
Study: 8314007

Group type: EXPERIMENTAL
Intervention: Human Insulin (HI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Porcine Insulin (PI)
Number of subjects: 30
Study: 3292105

Group type: EXPERIMENTAL
Intervention: Pinacidil (12.5 to 75 mg b.i.d.)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Prazosin (1 to 10 mg b.i.d.)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 401

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Pinacidil and Prazosin
Number of subjects: 401
Study: 8292068

Group type: EXPERIMENTAL
Intervention: Metamizole
Number of subjects: 74

Group type: COMPARATOR
Intervention: Butylscopolamine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 74
Study: 359247

Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg
Number of subjects: 161

Group type: COMPARATOR
Intervention: Aspirin 600 mg
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Diflunisal 125 mg
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Diflunisal 250 mg
Number of subjects: 161
Study: 30290299

Group type: EXPERIMENTAL
Intervention: Quitline
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: NRT
Number of subjects: 1047
Study: 27768399

Group type: EXPERIMENTAL
Intervention: Coconut Water (CW)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water (PW)
Number of subjects: 10
Study: 26400458

Group type: EXPERIMENTAL
Intervention: Vercirnon 500 mg once daily
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Vercirnon 500 mg twice daily
Number of subjects: 608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: All groups (placebo, once daily, twice daily)
Number of subjects: 608
Study: 24457277

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration during primary PCI (aspiration group, n=33)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Primary PCI without thrombus aspiration (non-aspiration group, n=30)
Number of subjects: 63
Study: 22456864

Group type: EXPERIMENTAL
Intervention: Patient led CGM
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Physician driven CGM
Number of subjects: 197

Group type: COMPARATOR
Intervention: Conventional self-monitoring of blood glucose (Control)
Number of subjects: 197
Study: 19038406

Group type: EXPERIMENTAL
Intervention: Trimipramine monotherapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Amitriptyline and haloperidol combination
Number of subjects: 94
Study: 17307427

Group type: EXPERIMENTAL
Intervention: Zofenopril 30 to 60 mg, n = 177
Number of subjects: 349

Group type: COMPARATOR
Intervention: Placebo, n = 172
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Zofenopril 30 to 60 mg
Number of subjects: 349

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study: 12774855

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day for 12 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/day for 12 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 53
Study: 10952477

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg on day 1 and 200 mg on days 2-4)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8979382

Group type: EXPERIMENTAL
Intervention: Success context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Failure context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highly contingent relationship priming
Number of subjects: 0
Study: 1487412

Group type: EXPERIMENTAL
Intervention: Interferon alfa 2b (IFN) 5.0 MU three times a week for one year
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (nothing)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Interferon alfa 2b (IFN)
Number of subjects: 48
Study: 2857739

Group type: EXPERIMENTAL
Intervention: Prazosin (0.5 mg by dry powder inhalation)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 mcg by pressurized aerosol)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (20 mg lactose by dry powder inhalation)
Number of subjects: 16
Study: 31232179

Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 21189

Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 21189

Group type: COMPARATOR
Intervention: Control (poster and traditional brochure)
Number of subjects: 21189
Study: 28543642

Group type: EXPERIMENTAL
Intervention: Off-CPB
Number of subjects: 100

Group type: COMPARATOR
Intervention: On-CPB
Number of subjects: 100
Study: 26422466

Group type: EXPERIMENTAL
Intervention: Expanded visit with questions modeled after a CIM consultation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acidil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard visit based on an empathic conventional primary care evaluation
Number of subjects: 24
Study: 23642006

Group type: EXPERIMENTAL
Intervention: Femtosecond laser CCI (2.75-mm three-plane)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Manual CCI (2.75-mm using disposable angled knives)
Number of subjects: 14
Study: 21501334

Group type: EXPERIMENTAL
Intervention: Mosapride 40mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 19901122

Group type: EXPERIMENTAL
Intervention: Rapidly cycled tandem high-dose therapy (HD); 2 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² every 14 days, followed by 2 cycles of epirubicin 90 mg/m², cyclophosphamide 3000 mg/m², and thiotepa 400 mg/m² every 21 days.
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: High YB-1 patients receiving HD
Number of subjects: 211

Group type: COMPARATOR
Intervention: Conventional dose-dense chemotherapy (DD); 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m², followed by 3 cycles of cyclophosphamide 600 mg/m², methotrexate 40 mg/m², and fluorouracil 600 mg/m² every 14 days.
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: High YB-1
Number of subjects: 211
Study: 18034211

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg IV once daily followed by oral moxifloxacin 400 mg once daily
Number of subjects: 161

Group type: COMPARATOR
Intervention: Ceftriaxone 2 g IV once daily followed by oral cefuroxime axetil 500 mg twice daily
Number of subjects: 161
Study: 15308999

Group type: EXPERIMENTAL
Intervention: Post-menopausal hormone therapy
Number of subjects: 397

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 397
Study: 11403816

Group type: EXPERIMENTAL
Intervention: Sensory discrimination training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (medically treated patients)
Number of subjects: 0
Study: 9253136

Group type: EXPERIMENTAL
Intervention: Videotape modeling smoking cessation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Brief smoking cessation advice and tipsheet
Number of subjects: 60
Study: 7802493

Group type: EXPERIMENTAL
Intervention: Combined burrow destruction and removal of chenopods in Karameh
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group in Sweimeh
Number of subjects: 0
Study: 3092967

Group type: EXPERIMENTAL
Intervention: Bismuth salicylate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31106491

Group type: EXPERIMENTAL
Intervention: Prenatal lipid-based nutrient supplements (LNS)
Number of subjects: 4011

Group type: COMPARATOR
Intervention: Iron and folic acid (IFA)
Number of subjects: 4011
Study: 26482244

Group type: EXPERIMENTAL
Intervention: Onion skin extract powder (approximately 163 mg quercetin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pure quercetin dihydrate (134 mg quercetin aglycone equivalent)
Number of subjects: 12
Study: 23183440

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL) 400 mg twice a day plus tenofovir-emtricitabine (TDF/FTC) 300 mg/200 mg once daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Raltegravir (RAL) twice a day plus TDF/FTC (from QDMRK study)
Number of subjects: 38
Study: 21723096

Group type: EXPERIMENTAL
Intervention: D-cycloserine 50mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 19855308

Group type: EXPERIMENTAL
Intervention: Free weight squat
Number of subjects: 6

Group type: COMPARATOR
Intervention: Smith machine squat
Number of subjects: 6
Study: 18200771

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 0
Study: 15117503

Group type: EXPERIMENTAL
Intervention: Procaine penicillin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 31
Study: 10886122

Group type: EXPERIMENTAL
Intervention: Oral administration of lefradafiban
Number of subjects: 12

Group type: COMPARATOR
Intervention: Jejunal administration of lefradafiban
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ileal administration of lefradafiban
Number of subjects: 12

Group type: COMPARATOR
Intervention: Colonic administration of lefradafiban
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Urinary excretion after oral, jejunal, and ileal applications
Number of subjects: 12

Group type: COMPARATOR
Intervention: Urinary excretion after rectal administration
Number of subjects: 12
Study: 9040998

Group type: EXPERIMENTAL
Intervention: Linear array EUS
Number of subjects: 79

Group type: COMPARATOR
Intervention: Radial scanning EUS
Number of subjects: 79
Study: 8201373

Group type: EXPERIMENTAL
Intervention: Hydrazine sulfate
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 3477355

Group type: EXPERIMENTAL
Intervention: Dentists with experience in treating fearful children
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dentists without experience in treating fearful children
Number of subjects: 24
Study: 29333843

Group type: EXPERIMENTAL
Intervention: Identification bracelet placed on the forearm
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Identification bracelet placed on the leg
Number of subjects: 914
Study: 27232153

Group type: EXPERIMENTAL
Intervention: 10mg Lercanidipine (LER)
Number of subjects: 59
Study: 26631224

Group type: EXPERIMENTAL
Intervention: SAMBA model for integrated OA care, including physiotherapist-led patient OA education sessions and an exercise programme lasting 8-12 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SAMBA model for integrated OA care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual OA care
Number of subjects: 0
Study: 23177313

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin (high-dose)
Number of subjects: 215

Group type: COMPARATOR
Intervention: 20 mg atorvastatin (low-dose)
Number of subjects: 215
Study: 21684096

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 236

Group type: COMPARATOR
Intervention: LNG-IUS
Number of subjects: 236